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Abstract
Aims: There have been few reports on whether long‐term oral phosphodies-
terase 5 inhibitor administration can ameliorate bladder changes due to
bladder outlet obstruction (BOO). Therefore, we clarified the chronological
changes of the bladder using male BOO rats and evaluated the effects of ta-
dalafil on these changes.
Methods: Eight‐week‐old male Sprague‐Dawley rats were used. BOO was
created by placing a polyethylene catheter around the urethra. Then, the rats
were orally treated with a vehicle, or tadalafil 2 or 10 mg/kg until each eva-
luation period. Cystometric measurements were performed and the degree of
fibrosis in the smooth muscle layer was evaluated at 2, 4, and 16 weeks.
Results: In BOO rats, a significant increase in the number of non‐voiding
contractions (NVCs) and a shortened intercontraction interval (ICI) were ob-
served in the earlier phase (2 and 4 weeks) compared to Sham rats. In the
chronic phase (16 weeks), markedly increased residual urine volume and an
extended ICI were observed accompanied by enhanced smooth muscle fibrosis.
These results indicated that the bladder in BOO rats represented the overactive
phenotype in the earlier phase and changed into the underactive phenotype in
the chronic phase. Even in Sham rats, an increased number of NVCs and
enhanced fibrosis were observed with time. Tadalafil administration sig-
nificantly prevented these bladder changes in both BOO and Sham rats.
Conclusions: Long‐term oral administration of tadalafil can prevent func-
tional and histological changes in the BOO rat bladder. This agent is also
effective for the bladder functional change even in non‐obstructed rats.
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1 | INTRODUCTION
Bladder outlet obstruction (BOO) such as benign pro-
static hyperplasia (BPH) in men typically causes storage
symptoms due to detrusor overactivity (DO) in the earlier
phase, and yet, over the long‐term clinical course, this
changes into voiding symptoms due to detrusor under-
activity (DU) in the chronic or terminal phase.1
In the bladder wall with BOO, repeated ischemia and
reperfusion cause partial denervation and changes of the
urothelium or detrusor muscle resulting from oxidative
stress2,3 and DO arises. Meanwhile, the detrusor muscle
maintains the urinary stream by becoming hypertrophic
and increasing intravesical pressure against BOO.4
However, contractile disability occurs when the detrusor
muscle cannot compensate for ischemic influences such
as changes of gap junctions5 or bladder wall fibrosis6 in
the terminal phase of BOO. As noted above, bladder
ischemia contributes largely to lower urinary tract
symptoms (LUTS) associated with BOO.
Phosphodiesterase 5 (PDE5) inhibitors block the re-
solution of cyclic guanosine monophosphate and cause
relaxation in the smooth muscle. Although PDE5 in-
hibitors have been used for erectile dysfunction treat-
ment, they also demonstrated improvement of LUTS with
blood flow increasing in the urinary bladder.7 Tadalafil
has become a therapeutic option for LUTS/BPH.
In basic experiments, a previous report demonstrated
that continuous treatment with a PDE5 inhibitor im-
proved the bladder contractility in BOO rats.8 However,
there have been few reports showing whether long‐term
PDE5 inhibitor administration can improve long‐term
changes in the bladder function from DO to DU in BOO
models. In particular, no report has proven the effects of
PDE5 inhibitors on the DU phenotype determined phy-
siologically with cystometry.
Therefore, we set two goals to evaluate the effects of
tadalafil on the bladder changes with BOO. First, to
evaluate the long‐term natural course of the bladder
function in BOO rats. We assumed that the bladder
function with BOO presents DO in early phase and pro-
gresses to DU in advanced phase. Second, to examine the
effect of long‐term administration of tadalafil on the re-
presentative bladder function in BOO rats. Consequently,
we examined whether early initiation and long‐term ad-
ministration of tadalafil could prevent the chronological
changes of bladder with BOO. To achieve these goals, we
evaluated the functional and structural changes of the
bladder in BOO rats, which were reported previously.9
Generally, the bladder function of rats has differences
between the sexes.10 In the present study, we chose male
rats because we intended to examine the bladder function
with male LUTS due to BPH by using these rats.
2 | MATERIALS AND METHODS
2.1 | Animals
Male Sprague‐Dawley rats (8 weeks old, 240‐290 g; Nihon
SLC, Shizuoka, Japan) were used. The rats were kept
under standard laboratory conditions with a 12 hours
light‐dark cycle, and free access to food and water. The
experimental protocol was approved and conducted in
compliance with the guidelines of the Animal Experi-
ment Committee of the University (15‐090) and con-
formed to the Guide for the Care and Use of Laboratory
Animals, 8th edition published by Institute for Labora-
tory Animal Research.
2.2 | Surgical procedures to create BOO
BOO was created based on the methods described
previously.9,11 Briefly, the rats were anesthetized with
isoflurane. After an abdominal midline incision, the
prostate was gently retracted to expose the bladder neck
and proximal urethra. A PE‐200 polyethylene catheter
with an inner diameter of 1.40 mm (Clay Adams,
Parsippany, NJ, USA) was used to create BOO. The side
of a 2 mm piece of the catheter was cut open and placed
around the proximal urethra. Sham rats underwent
only exposure of the proximal urethra and served as
controls.
2.3 | Drugs
Tadalafil (European Pharmacopoeia Reference
Standard) was suspended in 0.5% (wt/vol) methylcellu-
lose solution, and the suspension was prepared to be
1mL per animal per dose. Each rat was treated orally
once a day from the day after surgery to each evaluation
point with a vehicle (0.5% [wt/vol] methylcellulose so-
lution) (V group), 2 mg/kg (T2 group) or 10mg/kg
(T10 group) tadalafil. Drugs were injected into the
stomach using animal feeding needles. The dosages of
tadalafil in our experiment (2 or 10mg/kg daily) were
higher than the clinical dose for men with BPH. In
particular, tadalafil at 10mg/kg daily for rats corresponds
to 40mg/day for humans, which is a clinical dose for
patients with pulmonary hypertension.12 However, 2 mg/
kg has been used for animal experiments using BOO
rats13 and rats with chronic bladder ischemia.14 Fur-
thermore, 10 mg/kg of tadalafil was also used for BOO
rats.15 We used two dosages of tadalafil in the rat
model: 2 mg/kg as a standard dose and 10mg/kg as a
high dose.
2.4 | Evaluations
Each group of rats was evaluated by histology and cy-
stometry at 2, 4, and 16 weeks after surgery.
SHINKAI ET AL. | 1331
2.4.1 | Histological examinations
The rats were killed humanely by intracardiac injection of
pentobarbital (100mg/kg). Then, the urinary bladder was
dissected and fixed in 10% formalin neutral buffered solution
after bladder weight measurement. The fixed bladder was
axially divided into three sections, subsequently embedded in
paraffin and cut into 4 µm sections. Masson's trichrome
staining was performed. The degree of fibrosis was assessed
by the ratio of the smooth muscle area divided by the col-
lagen deposition area.16 The ratio was measured in three
randomly selected views of each level of the bladder, and the
average of them was defined as the muscle‐collagen ratio in
each animal. The specimens were photographed using a light
microscope (BZ‐9000; Keyence, Osaka, Japan) and analyzed
with computerized imaging software (BZ‐II; Keyence).
2.4.2 | Cystometric measurements
Two days before cystometry, a PE‐50 catheter (Clay
Adams) with a cuff was inserted into the bladder through
a small incision at the bladder dome and fixed by ligation.
A subcutaneous tunnel to the posterior neck of the rat
was created. The catheter was connected to an MLT0670
pressure transducer (ADInstruments, Castle Hill, NSW,
Australia) and an NE1000 syringe pump (New Era Pump
Systems, Farmingdale, NY).
Continuous cystometry was performed in the awake
state with saline infusion at a rate of 6mL/h for Sham rats
and 10mL/h for BOO rats based on previous reports11,16
and the results of preliminary experiments. A PowerLab
system and LabChart software (ADInstruments) were used
for data acquisition. The following cystometric parameters
were analyzed: the basal pressure, threshold pressure (TP),
maximum pressure (MP), voided volume (VV), average
urinary flow rate (Qave), intercontraction interval (ICI), and
mean amplitude and the number of non‐voiding contrac-
tions (NVCs).10 NVCs are bladder contractions without
micturition observed in the end of the storage phase.
Contractions with the amplitudes of more than 3 cmH2O
for 3minutes before micturition were defined as NVCs in
this study.16 Residual urine volume (RV) was measured by
direct bladder puncture immediately after cystometry.
Three consecutive typical cystometric curves were used for
evaluation, and the average values of each parameter were
considered representative ones for each animal.
2.5 | Statistical analysis
All of the data are shown as mean ± SD. The differences
between Sham and BOO groups were analyzed for
statistical significance by using the Student t test. The
differences among three groups such as evaluated periods
(2 weeks vs 4 or 16 weeks) or drug doses (V group vs T2 or
T10 group) were analyzed using one‐way analysis of var-
iance followed by Dunnett's test. P< .05 was considered
statistically significant. Statistical analysis was performed
using EZR.17
3 | RESULTS
In the Sham group, 35, 37, and 36 rats underwent the
operation for 2‐, 4‐, and 16‐week evaluation, respectively.
No rat died in the Sham group. On the other hand, in the
BOO group, 16 of 64, 15 of 56, and 20 of 57 rats failed to
complete the process after the creation of BOO because of
death. Furthermore, a total of 42 rats in both groups were
excluded from cystometric evaluation because the curves
were unmeasurable. Finally, data acquired from 99 BOO
rats (37, 32, and 30 rats at 2, 4, and 16 weeks, respec-
tively) and 93 Sham rats (30, 31, and 32 rats at 2, 4, and 16
weeks, respectively) were used for evaluation.
3.1 | Bladder weight and histological
examinations
3.1.1 | Time‐dependent changes in Sham
rats and changes induced by BOO
Bladder weight in Sham rats was almost unchanged from
2 to 16 weeks. In BOO rats, on the other hand, bladder
weight at 16 weeks seemed to be increased compared
with that at 2 weeks without a significant difference
(558.8 and 353.0 mg; P= .360). There was no significant
difference in the bladder weight at 2 weeks between
Sham and BOO rats (114.4 and 353.0 mg; P= .140).
However, that in BOO rats increased significantly com-
pared to Sham rats at 4 (247.8 and 117.8 mg; P< .001) and
16 weeks (558.8 and 124.1 mg; P= .012).
Representative histological images are shown in
Figure 1. Although the bladder wall and muscle layer
thickness were difficult to compare because the degree of
bladder extension differed in each animal, the muscle
layer of BOO rats appeared to be thicker than that in
Sham rats at 2 and 4 weeks (Figures 1A,B and 1D,E). In
contrast, it seemed to be thinner than in Sham rats at 16
weeks (Figures 1C and 1F). The smooth muscle‐collagen
ratio in Sham rats became lower over time, indicating
progression of fibrosis (Figure 2A). Collagen deposition
increased over time more prominently in BOO rats, and a
significant difference was observed compared to Sham
rats at 16 weeks (P< .001).
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3.1.2 | Effects of tadalafil on the bladder
weight and histology
No treatment effects of tadalafil on the bladder
weight changes were observed in any period in either
Sham or BOO rats. In the histological examination at
16 weeks, muscle layer atrophy seemed to be pre-
vented by tadalafil treatment, especially in BOO rats
(Figures 1F and 1I,J). Tadalafil treatment reduced
collagen deposition in both Sham and BOO rats at 16
weeks (Figure 2B).
3.2 | Cystometric measurements
3.2.1 | Time‐dependent changes of
cystometric parameters
The time‐dependent changes of cystometric parameters
are summarized in Table 1. Sham rats showed a sig-
nificant increase in the number of NVCs at 16 weeks
compared with that at 2 weeks (P= .024). In BOO rats,
ICI became markedly longer at 16 weeks compared with
2 weeks (P< .001). VV and RV markedly increased at 16
weeks compared with 2 weeks (each P< .001).
FIGURE 1 Representative histological images of the bladder with Masson's trichrome staining in Sham (A‐C) and BOO (D‐F) rats
(A and D: 2 weeks, B and E: 4 weeks, and C and F: 16 weeks after surgery). Bladder images of rats treated with tadalafil 2 mg/kg/day (T2)
(G: Sham, I: BOO) or 10 mg/kg/day (T10) (H: Sham, J: BOO) at 16 weeks are shown for comparison. A, B, D‐G, I, and J images are
representative ones from series including five animals per group. C and H images are from series including six animals per group. Smooth
muscle and collagen tissues are stained in red and light green, respectively. BOO, bladder outlet obstruction
FIGURE 2 Smooth muscle:collagen ratio (SCR) in the detrusor muscle layer. A, time‐dependent changes in Sham and BOO rats; B, the
effect of tadalafil on the changes of SCR in the Sham and BOO groups 16 weeks after surgery. Lower value of SCR indicates stronger fibrosis.
Scatter plot indicates measured values in each individual animal. Bar chart indicates mean ± SD in each group. *P< .05 (one‐way ANOVA
followed by Dunnett's test) vs 2w within each group, †P< .05 (unpaired t test) vs Sham‐V 16w group. 2w, 2 weeks after surgery; 4w, 4 weeks
after surgery; 16w, 16 weeks after surgery; T2, tadalafil 2 mg/kg/d; T10, tadalafil 10 mg/kg/day; V, vehicle
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3.2.2 | Comparison of the parameters
between Sham and BOO rats
In BOO rats, RV increased compared to Sham rats at all
evaluation periods, and the degree of the difference was
especially marked at 16 weeks (P= .005). At 2 weeks, the
number of NVCs significantly increased in BOO rats
compared with Sham rats (P< .001). Moreover, ICI in
BOO rats tended to be shorter than in Sham rats, though
there was no significant difference (P= .177). At 4 weeks,
in BOO rats, ICI was shortened and VV decreased sig-
nificantly compared with Sham rats (P= .002 and .005,
respectively), and the number of NVCs also increased in
BOO rats (P= .009). On the other hand, significantly
prolonged ICI (P< .001) and increased VV (P= .002)
were observed compared with Sham rats at 16 weeks.
3.2.3 | Effects of tadalafil on cystometric
parameters
The effects of tadalafil on cystometric parameters in Sham
rats at 16 weeks are shown in Figure 3. High‐dose tadalafil
prevented the increase in the number of NVCs (T2:
P= .069; T10: P= .014, respectively). ICI tended to prolong
in the T2 group compared with the Vehicle group
(P= .051); however, this effect was not observed in the T10
group (P= .692).The effects of tadalafil on BOO rats are
shown in Figure 4. A preventive effect on the increase in
the number of NVCs was observed at 2 weeks (T2:
P= .005; T10: P= .066). In the T10 group, the prolonged
ICI compared to Sham rats at 16 weeks significantly
shortened (P= .002). In addition, the increased RV seemed
to decrease, but that was not significant (P= .130).
4 | DISCUSSION
In this study, we first evaluated the long‐term natural course
of the bladder function in BOO rats. In general, rodent BOO
models present increased RV, elevated TP and MP, and an
increased number of NVCs as specific cystometric findings in
the DO phase.10 In our male BOO rat model, the number of
NVCs significantly increased compared to Sham rats at 2 and
4 weeks. These phases could be considered to represent the
DO phenotype, although the parameters of TP and MP did
not change. On the other hand, increased RV was considered
a finding that accompanied BOO. In the present study, it was
observed at all evaluation periods. Moreover, significantly
shortened ICI was observed in BOO rats compared to Sham
rats at 4 weeks.
Few reports have evaluated ICI in BOO animal
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technique similar to ours and reported prolonged ICI on
cystometry compared to Sham rats at 6 weeks. Although
it is difficult to compare their results with ours because
the evaluation periods were different, we consider the
shortened ICI on cystometry at around 4 weeks after
BOO creation in our experiment to be consistent with the
DO phenotype as men with BPH complain of frequent
urination in the overactive phase.
At 16 weeks, markedly increased RV and VV and
prolonged ICI were characteristics on cystometry in our
FIGURE 3 Effects of tadalafil on the changes of cystometric parameters in Sham rats 16 weeks after surgery. Scatter plot indicates
measured values in each individual animal. Bar chart indicates mean ± SD in each group. *P< .05 (one‐way ANOVA followed by Dunnett's
test) vs Sham‐V group within each group.group. ICI, intercontraction interval; NVCs, non‐voiding contractions; RV, residual urine volume;
T2, tadalafil 2 mg/kg/day; T10, tadalafil 10 mg/kg/day; V, vehicle; VV, voided volume
FIGURE 4 Effects of tadalafil on the changes of cystometric parameters in BOO rats classified by evaluated periods. Scatter plot
indicates measured values in each individual animal. Bar chart indicates mean ± SD in each group. *P< .05 (one‐way ANOVA followed by
Dunnett's test) vs BOO‐V group within each period.period. 2w, 2 weeks after surgery; 4w, 4 weeks after surgery; 16w, 16 weeks after surgery;
ICI, intercontraction interval; NVCs, non‐voiding contractions; RV, residual urine volume; VV, voided volume
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BOO rats. These findings were caused by bladder over-
extension and markedly decreased voiding efficiency. DU
in BOO animal models is defined as the development of
decompensation, but there has not been a definition
using cystometric parameters unlike DO.10 Considering
the clinical features of LUTS/BPH in men, these
cystometric findings in our BOO rats at 16 weeks were
compatible with the DU phenotype. Interestingly, the
number of NVCs significantly increased in Sham rats at
16 weeks.
We second evaluated the effects of long‐term adminis-
tration of tadalafil on the functional and structural changes
in the bladder. At 2 weeks, tadalafil administration to BOO
rats prevented the increased number of NVCs, and at 16
weeks high‐dose tadalafil prevented the prolonged ICI in-
duced by BOO creation. At 16 weeks, high‐dose tadalafil
also prevented the increased number of NVCs in Sham rats.
These results indicated that tadalafil could prevent both the
DO and DU phenotypes of bladder dysfunction after BOO
creation. Moreover, tadalafil could also prevent the bladder
functional change in chronic phase in non‐obstructed
rats.
Some reports have evaluated the effects of PDE5 in-
hibitors on the bladder function with BOO. Maciejewski
et al13 created BOO rats that were orally treated with
tadalafil 2 mg/kg/day for 16 weeks. Its administration
improved bladder capacity, compliance, and the fibrosis
due to BOO. However, they did not present detailed cy-
stometric measurements. On the other hand, Matsumoto
et al8 reported the results of isometric organ‐bath assay in
which oral administration of a PDE5 inhibitor (vardenafil
80 mg/kg) for 4 weeks to BOO rats improved the bladder
contractile function. As stated above, there has been no
report that evaluated the effect of PDE5 inhibitors on the
DU phenotype determined physiologically using cysto-
metry. In this respect, the present study is the first one to
establish the effects of long‐term tadalafil administration
on this phenotype.
While PDE5 inhibitors have preventive effects for the
bladder function with BOO as described above, the effects
of alpha‐1 blockers also have been reported. Okutsu
et al18 reported that 2 weeks tamsulosin administration to
BOO rats increased the bladder blood flow and amelio-
rated the decreased VV. This result seems to be similar to
our results at 2 or 4 weeks in which tadalafil prevented
overactive phenotype. On the other hand, the effect of
alpha‐1 blockers on prevention of DU has never been
reported.
In this study, the functional and morphological
changes of the bladder were seen not only in BOO
rats, but also in non‐obstructed rats. An increase in
the number of NVCs and enhanced bladder fibrosis
were observed even in Sham rats at 16 weeks.
Furthermore, tadalafil could alleviate these altera-
tions. Nomiya et al14 administrated tadalafil 2 mg/kg
daily for 8 weeks to rats with chronic bladder ischemia
and reported that tadalafil improved the frequent
voiding observed on cystometry and bladder fibrosis.
Although the model and evaluation period differed
from those in our study, similar changes in the blad-
der function occurred. Therefore, in our study, the
bladder ischemia might have caused the increased
number of NVCs and enhanced bladder fibrosis in
Sham rats. Moreover, these changes might be in-
hibited by improvement in the bladder blood flow due
to tadalafil. In fact, Kawai et al15 reported that tada-
lafil could improve the bladder blood flow in BOO
rats. Bladder ischemia in Sham rats might be caused
by the surgical manipulation around the bladder. Or,
we could also consider it to be caused by an aging
alteration of the bladder without BOO.
Our study has several limitations. First, this study
lacks evaluations of the bladder blood flow and molecular
alterations. Further experiments will be needed to elu-
cidate the mechanism of the present results. Second, it is
difficult to apply the present results directly to clinical
practice in men with LUTS/BPH, because of the species
difference, and the optimal dose and duration of tadalafil
administration are unknown. Third, tadalafil treatment
and evaluations were performed without any reduction of
BOO unlike clinical situation of BPH.
5 | CONCLUSION
In male BOO rats, functional changes in the bladder
from DO to DU are observed over time. Long‐term
administration of tadalafil can prevent both pheno-
types of bladder dysfunction. Histologically, tadalafil
can inhibit bladder fibrosis. The agent is also effective
for the bladder functional change even in non‐
obstructed rats.
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